August 2019: An update from CEO Russell Conley

Dear Members,

The Annual Scientific Meeting (ASM) has drawn to a close. The meeting was a very positive experience with insightful discussions and presentations. Thank you to everyone who attended, particularly those who presented their work and our Industry supporters who help to make the ASM happen.

I would like to congratulate everyone who received an AGITG Award at the ASM. In particular, I would like to congratulate Professor Val Gebski, who won the John Zalcberg OAM Award for Excellence in AGITG Research. Professor Gebski has made a remarkable contribution to the AGITG as a biostatistician since the formation of the group in 1991.

The AGITG Innovation Fund grant was awarded to Professor Peter Gibbs for the project ‘An organoid sensitivity testing driven umbrella study for patients with chemorefractory metastatic colorectal cancer’. This study will investigate a promising model for personalised therapy in an area of unmet need. The Innovation Fund is made possible through generous contributions from the Spencer Gibson Foundation, the His Honour Alan Bishop Fund and with donations made through the GI Cancer Institute’s Gutsy Challenge.

The AGITG is very proud of our Awards program supported by the organisation and Industry partners. Please find a complete list of Awards given on an annual basis here.

Dr Yu Jo Chua gave a presentation on the AGITG’s approach to international collaboration in cancer clinical trials at the Japanese Society of Medical Oncology Annual Meeting. He also presented a poster on INTEGRATE II, the first AGITG trial to open in a Japanese site. I would like to thank him for sharing his insights on our collaboration at the meeting.

Finally, consider making a donation to Professor Tim Price, leading the 2019 Southern Alps Gutsy Challenge, and Dr Lorraine Chantrill, leading our 2019 Cape to Cape Gutsy Challenge in support of GI cancer research. Thank you for supporting our gutsy members!

Please note that I will be away on long service leave from 2 September to 18 October inclusive.  Nisha Berthon-Jones, Clinical Research Manager, will be Acting CEO during this period.

Russell Conley
Chief Executive Officer